Data gathered: December 22
AI Stock Analysis - Editas Medicine (EDIT)
Analysis generated December 7, 2024. Powered by Chat GPT.
Editas Medicine is a genome editing company focused on developing transformative genomic medicines to treat serious diseases. Utilizing CRISPR technologies, Editas aims to create powerful therapeutics for genetically defined diseases. Their primary focus is on innovative therapies that can make an impactful difference in patient lives, with an overarching mission to harness the power of genome editing for human therapeutics.
Stock Alerts - Editas Medicine (EDIT)
 |
Editas Medicine | December 18 Price is down by -5.3% in the last 24h. |
|
Editas Medicine | December 16 Price is up by 8.7% in the last 24h. |
|
Editas Medicine | December 13 News Alert: Editas Medicine lays off 65% of staff and shelves lead gene-editing program |
|
Editas Medicine | December 13 Price is down by -9.5% in the last 24h. |
Alternative Data for Editas Medicine
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 1 | Sign up | Sign up | Sign up |
| Sentiment | 91 | Sign up | Sign up | Sign up |
| Webpage traffic | 15,000 | Sign up | Sign up | Sign up |
| Employee Rating | 68 | Sign up | Sign up | Sign up |
| Google Trends | 32 | Sign up | Sign up | Sign up |
| Patents | 87 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 10 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 17,009 | Sign up | Sign up | Sign up |
| Twitter Mentions | 6 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 40 | Sign up | Sign up | Sign up |
| Business Outlook | 51 | Sign up | Sign up | Sign up |
| Linkedin Employees | 340 | Sign up | Sign up | Sign up |
About Editas Medicine
Editas Medicine is a clinical-stage biotechnology company which is developing therapies based on CRISPR–Cas9 gene editing technology. Editas is based in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
| Price | $1.31 |
| Target Price | Sign up |
| Volume | 4,220,000 |
| Market Cap | $108M |
| Year Range | $1.31 - $6.08 |
| Dividend Yield | 0% |
| Analyst Rating | 24% buy |
| Industry | Biotechnology |
In the news
 |
XTX Topco Ltd Invests $179,000 in Editas Medicine, Inc. (NASDAQ:EDIT)December 21 - ETF Daily News |
|
Y Intercept Hong Kong Ltd Makes New $47,000 Investment in Editas Medicine, Inc. (NASDAQ:EDIT)December 20 - ETF Daily News |
|
Editas Medicine, Inc. (NASDAQ:EDIT) Shares Purchased by Fmr LLCDecember 18 - ETF Daily News |
|
Editas Medicine (NASDAQ:EDIT) Lowered to Underweight Rating by JPMorgan Chase & Co.December 17 - ETF Daily News |
 |
JPMorgan Downgrades Editas Medicine, Says Focus Shift Sparks Investor CautionDecember 17 - Biztoc.com |
 |
Editas Medicine (NASDAQ:EDIT) Price Target Lowered to $5.00 at Evercore ISIDecember 16 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 61,000 | 18M | -18M | -62M | 0 | -0.750 |
| Q2 '24 | 510,000 | 18M | -18M | -68M | -70M | -0.820 |
| Q1 '24 | 1.1M | 19M | -18M | -62M | -66M | -0.760 |
| Q4 '23 | 62M | 14M | 47M | -19M | -22M | -0.230 |
| Q3 '23 | 5.3M | 15M | -9.7M | -45M | -45M | -0.550 |
Insider Transactions View All
| Mei Baisong filed to sell 133,354 shares at $2.1. December 5 '24 |
| O'Neill Gilmore Neil filed to sell 312,106 shares at $2.1. December 5 '24 |
| Mei Baisong filed to sell 133,895 shares at $3.4. September 6 '24 |
| O'Neill Gilmore Neil filed to sell 313,724 shares at $3.4. September 6 '24 |
| Burkly Linda filed to sell 73,136 shares at $5.4. July 26 '24 |
Similar companies
Read more about Editas Medicine (EDIT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Editas Medicine?
The Market Cap of Editas Medicine is $108M.
What is the current stock price of Editas Medicine?
Currently, the price of one share of Editas Medicine stock is $1.31.
How can I analyze the EDIT stock price chart for investment decisions?
The EDIT stock price chart above provides a comprehensive visual representation of Editas Medicine's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Editas Medicine shares. Our platform offers an up-to-date EDIT stock price chart, along with technical data analysis and alternative data insights.
Does EDIT offer dividends to its shareholders?
As of our latest update, Editas Medicine (EDIT) does not offer dividends to its shareholders. Investors interested in Editas Medicine should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Editas Medicine?
Some of the similar stocks of Editas Medicine are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.